Microplasmin may eliminate need for surgery
Microplasmin, the drug aimed at patients with focal vitreomacular adhesion, is to be trialled at Southampton General Hospital. Injected directly into the eye earlier clinical studies have indicated that it has potential to be effective without the risks associated with surgery.
Microplasmin, the drug aimed at patients with focal vitreomacular adhesion, is to be trialled at Southampton General Hospital. Injected directly into the eye earlier clinical studies have indicated that it has potential to be effective without the risks associated with surgery.
The work has been spearheaded by Professor of Ophthalmology at the University of Southampton and consultant ophthalmologist at Southampton Eye Unit, Andrew Lotery and will be trialled at the Wellcome Trust Clinical Research Facility (WTCRF). "Southampton Eye Unit has worked with Wellcome Trust research nurses in 24 studies over the last six years," he said. "This has led to significant research breakthroughs and many patients have had their sight saved by being enrolled in our studies. My research programme would not be possible without the WTCRF."
Director of the WTCRF Dr Saul Faust said: "It is fantastic that the centre is able to support ground breaking research such as Andrew's that has such a positive impact on patient care."
